Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06929806 · ClinicalTrials.gov registry record · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
A Phase 3 study of Chronic Heart Failure and Iron Deficiencies, sponsored by Pharmacosmos A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,900
- Enrollment target
- 1
- Study location
NCT06929806 is a Phase 3 study of Chronic Heart Failure and Iron Deficiencies that is actively recruiting participants, run by Pharmacosmos A/S. The registered enrollment target is 1,900 participants, above the 264-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (620% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06929806, a Phase 3 study of Chronic Heart Failure and Iron Deficiencies, is actively recruiting participants, sponsored by Pharmacosmos A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,900 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency. The main question it aims to answer is: • How many participants are admitted to the hospital or die from a disease in the heart or blood vessels Researchers will compare treatment with ferric derisomaltose to no treatment with ferric derisomaltose. This will be done to see how well ferric derisomaltose works. Participants will: * Be randomized 50/50 to either treatment with Ferric derisomaltose or to no treatment with ferric derisomaltose * All participants receives standard of care * Visit site 4-5 times and have 7 video/phone-calls
Conditions Studied
Interventions
- DRUG Ferric Derisomaltose
Study Locations (1)
California
- Private clinic - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06929806
The ClinicalTrials.gov registry entry for NCT06929806 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 12 other Chronic Heart Failure trials with a reported enrollment target (620% higher). The listed sponsor is Pharmacosmos A/S, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Ferric Derisomaltose is the first listed.
NCT06929806 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06929806 about?
NCT06929806 is a clinical study titled "Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure". The goal of this clinical trial is to learn if the IV Iron treatment ferric derisomaltose helps in the treatment of chronic heart failure in people with iron deficiency. The main question it aims to answer is: • How many participants are admitted to the hospital or die from a disease in the heart o...
What is the current status of trial NCT06929806?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,900 participants. The study started on 2025-05-01. Estimated completion is 2027-12-01.
What conditions does trial NCT06929806 study?
This clinical trial studies the following conditions: Chronic Heart Failure, Iron Deficiencies.
What interventions are being tested in trial NCT06929806?
The interventions under investigation include: Ferric Derisomaltose (DRUG).
Who is sponsoring clinical trial NCT06929806?
This trial is sponsored by Pharmacosmos A/S, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06929806 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
RECRUITING · NA
-
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment
RECRUITING · NA
-
The HEARTFELT Study
RECRUITING · NA
-
R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances
ACTIVE NOT RECRUITING
-
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.